The new director at the FDA overseeing medical devices will confront criticisms about hasty approvals as she ushers in ...

Dr. Michelle Tarver, a veteran of the Food and Drug Administration (FDA), has taken charge of the FDA’s device division at a ...

The FDA’s breakthrough designation for Blindsight signals that the technology holds considerable promise and could contribute ...

Neuralink has claimed in a tweet that it has finally received approval from the FDA to start a first-in-human clinical trial of its brain implant chip – but hasn’t indicated when it may start.

Elon Musk's brain chip firm Neuralink has said that the US Food and Drug Administration (FDA) has approved its first human clinical trial, a critical milestone after earlier struggles to gain ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment.

Michelle Tarver, MD, PhD, a 15-year veteran of the agency, is stepping into a pivotal role as the new director of the FDA's device division, taking over for Jeffrey Shuren, MD. Dr. Shuren's tenure was ...

The US Food and Drug Administration (FDA) has awarded a "Breakthrough Device" status to Neuralink’s experimental vision-restoring implant, Blindsight. This designation is intended to fast-track ...

The FDA did not immediately reply to a Reuters' request for comment. The first two human applications targeted by the Neuralink device will be in restoring vision and enabling movement of muscles ...

Elon Musk’s substantial support for Donald Trump’s re-election has the potential to reshape regulatory oversight across his ...

The US Food and Drug Administration (FDA) is investigating whether semaglutide, the active ingredient of the weight loss drug Wegovy and the diabetes medication Ozempic, might cause hair loss and ...

Future of Healthcategory Musk's Neuralink says tiny wires of brain chip in first patient now stable July 11, 2024 Future of Healthcategory US FDA approves expanded use of Sarepta's Duchenne gene ...